Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 7 studies | 19% ± 3% | |
endothelial cell | 7 studies | 19% ± 2% | |
natural killer cell | 4 studies | 17% ± 0% | |
glutamatergic neuron | 3 studies | 24% ± 11% |
Insufficient scRNA-seq data for expression of FUT11 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 1547.57 | 578 / 578 | 100% | 14.83 | 1154 / 1155 |
breast | 100% | 1213.34 | 459 / 459 | 100% | 16.10 | 1114 / 1118 |
bladder | 100% | 1153.24 | 21 / 21 | 100% | 12.31 | 502 / 504 |
uterus | 100% | 1141.05 | 170 / 170 | 100% | 14.47 | 457 / 459 |
brain | 99% | 777.91 | 2628 / 2642 | 100% | 14.45 | 705 / 705 |
esophagus | 100% | 1263.36 | 1445 / 1445 | 99% | 12.43 | 182 / 183 |
thymus | 100% | 1066.42 | 653 / 653 | 99% | 13.73 | 601 / 605 |
prostate | 100% | 919.76 | 245 / 245 | 99% | 9.58 | 498 / 502 |
skin | 100% | 1114.31 | 1808 / 1809 | 99% | 14.95 | 466 / 472 |
kidney | 100% | 1133.00 | 89 / 89 | 98% | 34.25 | 885 / 901 |
intestine | 100% | 909.14 | 966 / 966 | 98% | 9.56 | 514 / 527 |
ovary | 100% | 1002.08 | 180 / 180 | 97% | 9.50 | 419 / 430 |
adrenal gland | 100% | 938.09 | 258 / 258 | 97% | 15.54 | 222 / 230 |
stomach | 99% | 605.27 | 354 / 359 | 96% | 9.76 | 274 / 286 |
pancreas | 95% | 460.98 | 313 / 328 | 99% | 16.82 | 176 / 178 |
liver | 96% | 481.51 | 218 / 226 | 69% | 4.75 | 281 / 406 |
adipose | 100% | 1468.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1604.90 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.45 | 29 / 29 |
spleen | 100% | 1698.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 14.08 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.99 | 1 / 1 |
heart | 100% | 1228.59 | 860 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 10.36 | 77 / 80 |
muscle | 96% | 444.56 | 772 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 1291.61 | 866 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006486 | Biological process | protein glycosylation |
GO_0036065 | Biological process | fucosylation |
GO_0000139 | Cellular component | Golgi membrane |
GO_0032580 | Cellular component | Golgi cisterna membrane |
GO_0046920 | Molecular function | alpha-(1->3)-fucosyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FUT11 |
Protein name | Alpha-(1,3)-fucosyltransferase 11 (EC 2.4.1.-) (Fucosyltransferase XI) (Fuc-TXI) (FucT-XI) (Galactoside 3-L-fucosyltransferase 11) (Fucosyltransferase 11) |
Synonyms | |
Description | FUNCTION: [Isoform 1]: Has minor fucosyltransferase activity toward biantennary N-glycan acceptors. Does not fucosylate GlcNAc residue within type 2 lactosamine unit. .; FUNCTION: [Isoform 2]: Has fucosyltransferase activity toward biantennary N-glycan acceptors. Does not fucosylate GlcNAc residue within type 2 lactosamine unit. . |
Accessions | Q495W5 ENST00000372841.8 [Q495W5-1] ENST00000394790.2 [Q495W5-2] |